Weight loss · Ohio
Weight loss and obesity studies in Ohio
34 studies have at least one recruiting site in Ohio. Weight-management research includes trials of new medicines, devices, diets and lifestyle programs for people with overweight or obesity, and studies of weight-related conditions such as fatty liver disease.
34 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
1 study with pay posted
Exact amounts posted by the research company for each study. The button opens that study’s own page.
Pays up to
$11,600
Overweight Healthy Adults, Ages 18–65
Medpace · Cincinnati, OH
13 outpatient visits (including screening) plus one 5-night stay and one 4-night stay at the Phase 1 unit.
Ages 18–65 · Male/Female
View study & apply (opens in a new tab)Opens Medpace’s page for this exact study
More recruiting studies (pay not posted)
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
Hanmi Pharmaceutical Company Limited
- Location
- Cincinnati, OH
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Columbus, OH + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Cincinnati, OH + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Pfizer
- Location
- Cincinnati, OH + 4 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- Dayton, OH + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Hoffmann-La Roche
- Location
- Columbus, OH + 44 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Pfizer
- Location
- Cincinnati, OH + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Columbus, OH + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly and Company
- Location
- Dayton, OH + 24 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Lima, OH + 59 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
- Location
- Cincinnati, OH + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- Cincinnati, OH + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Eli Lilly and Company
- Location
- Cincinnati, OH + 28 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Columbus, OH + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- Cincinnati, OH + 42 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
- Location
- Westlake, OH + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company
- Location
- Westlake, OH + 34 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk A/S
- Location
- Cincinnati, OH + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Amgen
- Location
- Cincinnati, OH + 30 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen
- Location
- Cincinnati, OH + 69 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S
- Location
- Columbus, OH + 26 other US sites
- Eligibility basics
- Ages 8–18
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Eli Lilly and Company
- Location
- Cincinnati, OH + 55 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk A/S
- Location
- Cincinnati, OH + 14 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice…
Eli Lilly and Company
- Location
- Boardman, OH + 38 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Most of these studies set a BMI range and may exclude people taking certain weight-loss medicines or who have had bariatric surgery. Some require a weight-related condition such as type 2 diabetes or high blood pressure.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Can I join a weight loss study if I already take a GLP-1 medicine?
It depends on the study. Many exclude people currently or recently on weight-loss medicines; others are designed specifically for them. The listing’s eligibility criteria and the study team are the only reliable answer.